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Background: Prader-Willi syndrome (PWS) is a complex human genetic disease that arises from lack of expression of 
paternally inherited imprinted genes on chromosome 15q11-q13.Prader-Willi syndrome. 
Objective: To use whole genome array to investigate observed Prader-Willi phenotype by assaying differential gene 
expression patterns in Prader-Willi like subjects.  
Methodology: Combined clinical and laboratory study. Three people who participated in a large study of Prader-Willi 
syndrome (PWS) were found to satisfy the criteria for a firm clinical diagnosis of the syndrome using the accepted 
consensus scores. A score of 8 is considered to be diagnostic for PWS but despite all three scoring >8, they were 
genetically negative for PWS. By using Affymetrix Cytogenetics Whole-Genome 2.7M arrays which identify both loss 
and gain in genomic DNA and also report loss of heterozygosity regions in which all three participants showed the 
same genomic abnormality were determined. By comparing these regions with the UCSC human genome database, a 
list of potential candidate genes was compiled in which the participants had all shown the same change.  Confirmation 
of altered gene expression was sought using qPCR to study transcription levels in each of the genes identified. 
Results: Three people who participated in the study showed both maternal and paternal bands after methylation-
specific PCR and they all expressed SNRPN. Increase in copy number with concomitant elevated transcription levels 
were found in SGSM2 which had previously been associated with severe obesity and in the protein-folding gene PPIF.  
Conclusion: Over-expression caused by duplication may be a contributing factor to the PWS-like phenotype in these 
people. 
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1. Introduction 
Prader-Willi syndrome (PWS) is characterised by 
obesity, short stature, small hands and feet, neonatal 
hypotonia with difficulty in feeding at birth, 
hypogonadism and eye problems. At about two years of 
age the feeding difficulties with poor suck are gradually 
replaced by hyperphagia and obsession with food, 
leading to the obesity. In addition to developmental 
delay which is manifested by short stature, small hands 
and feet, growth hormone deficiency and 
hypogenitalism/hypogonadism, there are also 
behavioural characteristics including learning 
disabilities, temper tantrums, aggression, repetitive 
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speech, obsessive compulsive behaviour, sleep disorder 
and skin picking (Cassidy and Driscoll, 2009). This 
disparate collection of symptoms led Holm et al (1993) 
to define the major and minor characteristics which 
allowed a clinical diagnosis of this the most common 
genetic form of obesity. Consensus diagnostic criteria 
were defined and weighted scores in which the major 
criteria were awarded one point and the minor criteria 
half a point calculated. A score of 8 or more is clinically 
diagnostic for PWS. 
The majority of people with PWS have a paternally 
derived deletion of approximately 5-7Mb  in 15q11-q13, 
others have maternal disomy of chromosome 15 
(UPD15mat) and a minority have a defect of the 
imprinting centre located in exon 1 of the SNRPN gene 
which leads to a maternal imprint on the paternally 
derived chromosome. Any of these abnormalities will 
result in loss of the paternal contribution to the Prader-
Willi syndrome critical region (PWSCR), demonstrated 
by loss of a paternally derived unmethylated band at the 
imprinting centre and a lack of expression of the SNRPN 
gene. Although these do not differentiate between the 
different genetic types of PWS they are diagnostic for 
the syndrome (Cassidy and Driscoll, 2009; Ramsden et 
al, 2010; Zeschnigk et al, 1997).  
Within 15q11-q13 the complex imprinted 
SNURF/SNRPN gene hosts several untranslated snoRNA 
genes located within intronic sequences. The finding of 
a microdeletion involving SNORD116 in a boy with PWS 
led to the identification of this snoRNA as the candidate 
gene for the syndrome (Sahoo et al, 2008).  
In the course of a large study of PWS in the UK 
(Whittington et al, 2001; Soni et al, 2007) three people 
were identified who fulfilled the criteria for a clinical 
diagnosis of the syndrome but not the genetic 
laboratory diagnostic criteria.  
The Affymetrix Cytogenetics Whole-Genome 2.7M array 
while providing high resolution whole genome coverage 
reliably detects changes in copy number. Deletions 
and/or duplications present in all three participants if 
involved in annotated genes could potentially 
contribute to the Prader-Willi-like phenotype. 
Candidate genes can subsequently be evaluated to 
estimate their transcription levels and compared with 
those shown by people with PWS and with unaffected 
individuals. 
2. Methods 
2.1 Study subjects 
The three subjects in this study had all been 
participants in a population study of PWS carried out in 
the UK (Whittington et al, 2001; Whittington et al, 2002; 
Soni et al, 2007). Each was assessed by the clinical 
criteria of Holm et al (1993). Genetic testing was carried 
out blind to the results. Despite the fulfilment of the 
clinical criteria with all three scoring >8 (Table 1), 
genetic testing proved negative.  Participant 2 (also case 
2 in Whittington et al, 2002) had a clinical diagnostic 
score of >15. 
 
Table 1: Clinical data for three people with 
characteristics of Prader-Willi syndrome 
Criterion 
Participant 
1 2 3 
Floppy at birth yes yes yes 
Poor suck yes yes yes 
Feeding problems yes yes yes 
Obesity if no intervention yes yes yes 
Hypogonadism yes yes ? 
Developmental delay/ID yes yes yes 
Food foraging or obsession yes yes yes 
    
Behavioural problems yes yes yes 
Sleep disturbance ? yes no 
Short height for family yes yes ? 
Skin picking yes yes yes 
    
Scoliosis yes no no 
Bruises easily yes ? yes 
 
2.2 Molecular Studies 
Nucleic acids were extracted from peripheral blood 
lymphocytes according to manufacturers’ protocols and 
stored at -80°C.  RNA was isolated using TRI-reagent 
(Sigma, UK) and DNA using Puregene methodology 
(Qiagen, UK). Quality and concentration were estimated 
using Nanodrop ND-1000 UV-Vis spectrophotometry.  
Genetic analysis for PWS was carried out both by 
bisulphite treatment of genomic DNA followed by 
methylation-specific PCR (MS-PCR) at the SNRPN (exon 
1) locus and by expression of the SNRPN gene 
(Zeschnigk et al, 1997; Kubota et al, 1997; Ramsden et 
al, 2010). Microsatellite analysis was used to determine 
zygosity within 15q11-q13.  
For expression studies, RNA (1-5µg) was treated with 
DNAse1 prior to cDNA synthesis using a high capacity 
reverse transcription kit (Applied Biosystems) with 
random hexamers as primers. 
The integrity of the PWSCR was investigated by 
sequencing genomic DNA using primers from genes 
located within 15q11-q13. Individual primers from all 
29 copies of SNORD116 were designed within flanking 
sequences unique to each member of the cluster, 
ensuring distinction between individual copies and 
where possible including SNPs. Primer sequences were 
derived using Primer 3 (http://frodo.wi.mit.edu) and 
sequencing was carried out using BigDye Terminator 
technology (Applied Biosystems). Copy number at the 
IPW locus was determined by real time qPCR of 
genomic DNA using GUSB as the reference gene and 
expression levels at a series of genes from 15q11-q13 
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were obtained by qPCR using cDNA and SYBR Green 
technology (Applied Biosystems). Reference genes were 
GAPDH and ACTB. Quantitative PCR was carried out 
according to MIQE guidelines (Bustin et al, 2010).
 
Table 2:  Laboratory criteria for three people with a firm clinical diagnosis of PWS 
 Subject 1 Subject 2 Subject 3 Controls 









SNRPN expression 0.7 0.6 4.0 1.0±0.1, n=9 
PAR5 expression 1.1 0.5 2.0 1.0±0.1, n=10 
SNORD116 expression 0.5 0.7 1.0 1.0±0.3, n=14 
IPW expression 2.3 1.7 3.3 1.0±0.4, n=5 
UBE3A expression 1.6 0.9 ND 1.0±0.1, n=14 
ATP10A expression 1.4 1.0 ND 1.0±0.1, n=30 
GABRB3 expression 1.5 1.4 1.0 1.0±0.4, n=16 
Alleles at D15S128 203, 206 203, 206 206, 209  
Alleles at D15S822 (GABRG3) 289, 296 289, 296 260, 270  
Copies of IPW 1.6 1.9 2.2  
Conclusion Not PWS Not PWS Not PWS  
ND = not done;  n=number of individuals  
Note: To normalise the Ct values standard curves for the target gene and the reference gene were plotted using the same control and 
relative expression calculated from the standard equations. The ∆Ct method was then used to determine the relative expression values 
for the participants and a series of control individuals averaged as one. Expression values were calculated for a series of at least 4 
separate control and PWS  individuals 
Table 3: Informative SNPs either inside or close to genes within the PWSCR 
Gene SNP id SNP  Subject 1 Subject 2 
MAKORIN3 rs2239669 C/T C/T C 
NDN rs2192206 C/T C/T C/T 
SMP (SNRPN minimal promoter) rs220030 A/G T/C T 











IPW Exon 1 
IPW Exon 3 













PAR 1 rs2249378 C/T A/G G 
 
2.3 Array analysis 
DNA samples from each participant were processed 
according to the Affymetrix Cytogenetics Array protocol 
(http://media.affymetrix.com/support/downloads/ma
nuals/cyto assay usermanual.pdf) then hybridised to 
Affymetrix Cytogenetics Whole-Genome 2.7M arrays 
and the results analysed using the Affymetrix 
Chromosome Analysis Suite (ChAS). These results were 
evaluated by identifying overlapping areas of genomic 
change shown by all three of the study participants. The 
location and size of each shared alteration obtained 
from the analysis identified potential candidate genes 
and their expression levels were ascertained by real-
time qPCR. 
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The mRNA sequence for each gene was obtained from 
the UCSC or NCBI databases (http://genome.ucsc.edu/; 
http://www.ncbi.nlm.nih.gov). Where possible primer 
pairs spanning an intron/exon boundary were chosen 
and each pair was first studied by in vitro PCR to ensure 
that any product was unique and that different isoforms 
of the same gene would be detected.  
 
Table 4: Expression levels of annotated candidate genes in which all three participants demonstrated the same 






Subject 1 Subject 2 Subject 3 PWS mUPD 
PWS 15q11-
q13del 
ACY 3p21.1 3 1.0±0.2, n=4 0.8 NR 0.5 0.4±0.04, n=4 0.9±0.2, n=4 
RPL29 3p21.1 3 1.0±0.2, n=4 0.9 6.3 1.9 1.2±0.2, n=4 3.5±1.4, n=4 
SERF1B 5q13.2 1 1.0 NR NR 0.5 2.0 2.1 
SMN2 5q13.2 1 1.0 2.8 5.9 0.3 1.5 0.3 
OCLN 5q13.2 1 NR NR NR NR NR NR 
NAIP 5q13.2 1 1.0±0.6, n=6 1.0 NR 1.0 0.8±0.6, n=6 1.3±0.6, n=5 
KIF25 6q27 1 1.0 NR NR NR 1.0 0.8 
POLR2J 7q22.1 1 1.0 0.4 3.8 0.1 1.5 0.3 
RASA4 7q22.1 1 NR NR NR NR NR NR 
CNTNAP3 9p13.1 1 1.0±0.3, n=13 1.8 2.3 1.8 0.8±0.4, n=9 1.0±0.3, n=9 
PARG 10q11. 1 1.0 NR NR 1.0 1.8 1.7 
ZMIZ1 10q22 3 1.0±0.1, n=8 0.8 0.7 1.3 1.4±0.1, n=8 0.9±0.2, n=6 
PPIF 10q22 3 1.0±0.4, n=12 2.1 4.0 2.2 2.2±0.9, n=12 2.5±0.7, n=11 
GPHN 14q23 1 1.0 4.3 3.1 0.6 0.8 1.5 
APBA2 15q13 3 1.0±0.1, n=5 1.7 1.4 1.0 1.0±0.2, n=9 0.9±0.2, n=6 
NDNL2 15q13 1 1.0±0.2 0.6 1.3 1.0 1.6±0.5 1.3±0.4 
TJP1 15q13 1 NR NR NR NR NR NR 
CHRNA7 15q13 1 1.0 2.8 2.3 0.1 1.2 1.3 
NOMO2 16p12 1 NR NR NR NR NR NR 
EIF3C 16p11 1 1.0 0.8 2.7 0.1 1.3 0.2 
SGSM2 17p13 3 1.0±0.2, n=17 2.2 3.1 1.6 1.3±0.2, n=12 1.2±0.4, n=8 
MNT 17p13 3 1.0±0.2, n=10 2.0 NR 1.1 1.0±0.4, n=12 0.9±0.5, n=8 
FMNL1 17q21 3 1.0±0.2 1.1 0.5 0.8 0.9±0.2 0.6±0.2 
TCEB3C 18q21 1 1.0 1.6 2.1 0.1 1.1 2.5 
GGT1 22q11 1 1.0 1.0 0.8 0.5 0.7 0.3 
PCDH11 Xq21 gain 1.0 NR NR NR 1.1 1.4 
 
3. Results  
3.1 Molecular studies 
The three study participants all had normal G-banded 
karyotypes, they demonstrated both maternal and 
paternal bands after MS-PCR and they all expressed 
SNRPN (Whittington et al, 2002). These data exclude a 
genetic diagnosis of PWS (Jin, 2011).  Microsatellite 
analysis showed heterozygosity throughout 15q11-q13 
including at the SNRPN locus, gene scanning with 
fluorescent PCR detected two copies of GABRG3 and 
genomic qPCR detected two copies of IPW in each 
participant. Genes PAR5, SNORD116, IPW, UBE3A, 
ATP10A and GABRB3 were all expressed (Table 2). 
Following the sequencing of participant DNA in all 29 
copies of SNORD116, the current candidate gene for 
PWS, using primers distinguishing each individual copy, 
no point mutations or deletions were detected within 
the coding region of any copy of SNORD116.   
In subjects 1 and 2 sequencing of a series of other genes 
located within 15q11-q13 again did not detect  
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mutations in any coding region.These genes included 
MAKORIN3, NDN, SMP (SNRPN minimum promoter), 
SNRPN/SNURF, SNORD107, PAR5, SNORD64, IPW and 
PAR1.  Of 45 SNPs within the sequenced regions, subject 
1 was informative at 9 ranging from 15:21,362,686 in 
MAKORIN3 to 15:22,933,834 in PAR1and subject 2 was 
informative from 15:21,482,600 in NDN to 
15:22,912,959 in IPW (Table 3).  
Expression studies showed all three of the participants 
to express genes within 15q11-q13, showing that 
PWSCR is intact in all three participants. 
3.2 Array Results 
Genomic DNA from the three participants was studied 
alongside a sample from a PWS patient with del15q11-
q13pat. The array confirmed the presence of the 
deletion which was shown to be 5,957 kbp in size and 
also showed that it was not present in any of the three 
participants (Figure 1). Subject 3 did have a small 
deletion of 21kbp in a repetitive region near the PWRN2 
gene. 
The copy number throughout the region is shown on the Y axis 
by the coloured lines. The large PWS deletion and the small 
21kb deletion in subject 3 are shown as solid red bands. The 
numbers along the X-axis at the base of the figure show genomic 
position on chromosome 15 in kilobases (hg18). 
Figure 1: Array copy number analysis of 15q11-q13 for 
the three participants (cases 1-3) and a person with 
PWS due to a paternal deletion (PWS 15q11-q13del).  
 
The copy number throughout the region is shown on the Y axis 
by the coloured lines. The duplicated regions in the three 
subjects are shown as solid blue bands. The numbers along the 
X-axis indicate genomic position on chromosome 10 in kilobases 
(hg18) and the position of PPIF is shown below. 
Figure 2: Array copy number analysis of 10q22.3 for 
the three participants (cases 1-3) and a person with 
PWS due to a paternal deletion (PWS 15del).  
Loss of both alleles was not detected at any autosomal 
locus. So each deleted region was one of potential 
haploinsufficiency. When qRT-PCR was performed on 
seventeen genes to determine whether loss of a single 
copy resulted in a detectable deficiency of expression in 
dosage sensitive genes, no correlations were found 
between values obtained from the three subjects and 
people with PWS due either to matUPD or a 15q11-q13 
deletion or from control individuals (Table 4).  
Nine genes; ACY, RPL29, ZMIZ1, PPIF, APBA2, SGSM2, 
MNT, FMNL1 and PCDHI1 showed a gain in copy 
number for all three subjects. Two of these genes 
(SGSM2 and PPIF) which are located on 10q22.3 and 
17p13.3 respectively showed a copy number increase, 
(Figure 2 and 3) and (also had elevated transcription 
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levels when compared to controls. Normal transcription 
of SGSM2 was found in people with either of the 
common genetic types of PWS   but levels of PPIF were  
raised in people with PWS due to either matUPD or 
del15q11-q13 pat. (Table 4, Figure 4). Comparison 
with either genetic type of PWS using the Mann-
Whitney test showed that for PPIF, PWS due to either a 
deletion or maternal UPD differed from controls with p 
<0.05. 
 
The copy number throughout the region is shown on the Y axis 
for each subject by the coloured lines. The duplicated regions in 
the three subjects are shown by solid blue bands. The numbers 
along the X-axis indicate genomic position on chromosome 17 in 
kilobases (hg18) and the location of SGSM2 is shown below 
Figure 3  Array copy number analysis of 17p13.3 for 
the three participants (cases 1-3) and a person with 
PWS due to a paternal deletion (PWS15q11-q13del).  
 
Column 1 - control subjects; column 2 - participant 1; column 3 
– participant 2; column 4 – participant 3; column 5 - PWS due 
to UPD(15)mat;  column 6  - PWS with del15q11-q13pat. 
Figure 4:  Expression of SGSM2 and PPIF.    
 
4. Discussion 
This study has identified two genomic regions, 10q22.3 
and 17p13.3, common to three people in which 
duplications with resulting over expression of genes, 
may contribute to a PWS phenotype.  
Since PWS is a neurodevelopmental disorder, tissue 
specificity of gene expression could mean that genes 
highly expressed in brain may not be so in lymphocytes 
and vice versa. Despite this, some authors have 
employed both with no apparent problem [Hong et al., 
2008] and others have used lymphoblastoid lines in 
behavioural studies (Bittel et al, 2006; Nishimura et al, 
2007).  
Microdeletions in PWS subjects with negative molecular 
diagnostic tests have established snoRNA SNORD116 as 
a strong candidate gene (Sahoo et al, 2008; de Smith et 
al, 2009; Duker et al, 2010). In each of these studies, 
array genotyping led to the identification of a 
microdeletion (of ~200kbp) encompassing the entire 
snoRNA cluster. although expression of SNRPN 
remained. The Affymetrix Cytogenetics Whole Genome 
array should not have missed a deletion of this size and 
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did detect a much smaller microdeletion of 21kbp at a 
more proximal location within the PWSCR (Figure 1). 
In the present study each of three subjects also 
demonstrated a functional imprinting centre showing 
both methylated and unmethylated bands on MS-PCR. 
PWS could still have resulted from abnormalities such 
as a small deletion or a point mutation elsewhere in the 
PWSCR but sequencing did not detect a mutation in any 
15q11-q13 gene including SMP the SNRPN minimal 
promoter and SNORD116. Sequencing of MAKORIN3, 
SNRPN and IPW indicated two intact copies in both 
subjects 1 and 2 as they contained informative SNPs and 
all three participants had two alleles at D15S128 and 
D15S822. All three expressed candidate genes including 
SNORD116, SNRPN, IPW and also UBE3A, ATP10C and 
GABRB3. Taken together these data suggest that they all 
had two copies of the PWSCR, that genes within it were 
being normally expressed and that the PWS 
phenocopies were the result of downstream changes 
elsewhere in the genome. Substrates for SNORD116 are 
still not identified and its functional role is as yet 
unclear. 
Studies on candidate genes identified by array 
technology demonstrating loss or gain in copy number 
showed that no loss of an allele had led to a marked 
reduction of transcription in any of those identified but 
elevated transcription levels were observed in two 
putative obesity-related genes PPIF and SGSM2 where 
there was a gain in copy number. An increase in 
transcription levels of PPIF was also found in 
individuals with PWS due to either a 15q11-q13 
deletion or 15(UPD)mat, suggesting its possible 
involvement as a downstream gene contributing to the 
etiology of PWS.  
SGSM2 (OMIM 611418) which is upregulated in all three 
participants, is located within the small 17p13.3 gain 
described previously by Bochukova et al [2010] in a 
study of obesity. PPIF (OMIM 604486) or cyclophilin F 
potentiates neuronal and synaptic stress [Du et al 
2008]. Mice lacking the Ppif gene demonstrated 
improvement in both learning and memory when 
compared with controls and were also subject to adult-
onset obesity (Luvisetto et al, 2008).  
A bioinformatics screen (Bazeley et al, 2008) searching 
for guide sites for orphan C/D box snoRNAs located 21 
possible targets for SNORD116 within protein coding 
genes. One of the 21 purported targets for SNORD116 is 
PPIL2 which belongs to the same family and performs a 
similar function to PPIF while another, RASAL2 was 
hemizygous in participant 1. 
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